Adherence with lipid screening guidelines in standard- and high-risk children and adolescents - 23/01/21
, Feiyan Chen, PhD b, Jennifer A Faerber, PhD b, Michael L. O'Byrne, MD, MSCE a, c, d, 1, Julie A. Brothers, MD a, 1Background |
Because atherosclerosis begins in childhood, universal lipid screening is recommended with special attention to conditions predisposing to early atherosclerosis. Data about real-world penetration of these guidelines is not available.
Methods |
Retrospective cohort study using MarketScan® commercial and Medicaid insurance claims databases, a geographically representative sample of U.S. children. Subjects who passed through the 9- to 11-year window and had continuous insurance coverage between 1/1/2013 and 12/31/2016 were studied. Multivariable models were calculated, evaluating the association between other patient factors and the likelihood of screening. The primary hypothesis was that screening rates would be low, but that high-risk conditions would be associated with a higher likelihood of screening.
Results |
In total, 572,522 children (51% male, 33% black, 11% Hispanic, 51% Medicaid) were studied. The prevalence of high-risk conditions was 2.2%. In unadjusted and adjusted analyses, these subjects were more likely to be screened than standard-risk subjects (47% vs. 20%, OR: 3.7, 95% CI 3.5-3.8, P < .001). Within this group, the diagnosis-specific likelihood of screening varied (26–69%). Endocrinopathies (OR 5.4, 95% CI 5.2-5.7), solid organ transplants (OR 5.0, 95% CI 3.8-6.6), and metabolic disease (OR 3.9, 95% CI 3.1-5.0, all P < .001) were associated with the highest likelihood of undergoing screening.
Conclusions |
Despite national recommendations, lipid screening was performed in a minority of children. Though subjects with high-risk conditions had a higher likelihood of screening, rates remained low. This study highlights the need for research and advocacy regarding obstacles to lipid screening of children in the United States.
Le texte complet de cet article est disponible en PDF.Abbreviations : AAP, AHA, CKD, CVD, ICD, NDC, NHLBI
Plan
| Financial Disclosure: The authors have no financial relationships relevant to this article to disclose |
|
| Potential Conflicts of Interest: The authors have no conflicts of interest relevant to this article to disclose. |
|
| Contributors' Statement: Drs Berger and Brothers conceptualized and designed the study, drafted the initial manuscript, and reviewed and revised the manuscript. Drs Chen and Faerber designed the data collection instruments, collected data, carried out the initial analyses, and reviewed and revised the manuscript. Dr O'Byrne conceptualized and designed the study, coordinated and supervised data collection, and critically reviewed the manuscript for important intellectual content. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work. |
Vol 232
P. 39-46 - février 2021 Retour au numéro
Article précédent
- Oral anticoagulant use in patients with atrial fibrillation and mitral valve repair
- Ashwin S. Nathan, Lin Yang, Zhi Geng, Elias J. Dayoub, Sameed Ahmed M. Khatana, Paul N. Fiorilli, Howard C. Herrmann, Wilson Y. Szeto, Pavan Atluri, Michael A. Acker, Nimesh D. Desai, David S. Frankel, Francis E. Marchlinski, Alexander C. Fanaroff, Jay Giri, Peter W. Groeneveld
- Levothyroxine dose and risk of atrial fibrillation: A nested case-control study
- Inna Y. Gong, Clare L. Atzema, Iliana C. Lega, Peter C. Austin, Yingbo Na, Paula A. Rochon, Lorraine L. Lipscombe
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?